Compare Stocks

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CDXI Cardax		$0.00	$0.00 ▼ $0.00	N/A	-0.03	N/A	N/A
ETST Earth Science Tech	$0.06 +5.9%	$0.07	$0.00 ▼ $0.12	$19.37M	1.77	97,046 shs	120,310 shs
IMUC EOM Pharmaceuticals	$0.20	$0.22	$0.11 ▼ $0.40	N/A	0.37	3,795 shs	832 shs
NSPX Inspyr Therapeutics		$0.00	$0.00 ▼ $0.07	$1.47M	-17.33	13.19 million shs	29.64 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CDXI Cardax	0.00%	0.00%	0.00%	0.00%	0.00%
ETST Earth Science Tech	0.00%	-13.24%	-10.61%	-26.25%	+84.38%
IMUC EOM Pharmaceuticals	0.00%	+12.12%	-13.96%	-49.89%	-43.44%
NSPX Inspyr Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Move Your Money Before May 1 (Ad)

Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens?

Click here to get the full story before May 1.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CDXI Cardax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CDXI Cardax	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CDXI Cardax	N/A	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	$50K	387.48	N/A	N/A	N/A	∞
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CDXI Cardax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	-$370K	N/A	∞	N/A	5.77%	20.61%	11.73%	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	∞	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	-$6.30M	N/A	N/A	N/A	N/A	N/A	-1,354.49%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CDXI Cardax	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CDXI Cardax	N/A	N/A	N/A
ETST Earth Science Tech	0.10	0.87	0.39
IMUC EOM Pharmaceuticals	N/A	N/A	N/A
NSPX Inspyr Therapeutics	N/A	0.09	0.09

Ownership

Institutional Ownership

Company	Institutional Ownership
CDXI Cardax	N/A
ETST Earth Science Tech	N/A
IMUC EOM Pharmaceuticals	N/A
NSPX Inspyr Therapeutics	0.02%

Insider Ownership

Company	Insider Ownership
CDXI Cardax	29.50%
ETST Earth Science Tech	24.90%
IMUC EOM Pharmaceuticals	3.28%
NSPX Inspyr Therapeutics	0.02%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CDXI Cardax	10	825,000	N/A	Not Optionable
ETST Earth Science Tech	8	309.98 million	232.80 million	Not Optionable
IMUC EOM Pharmaceuticals	3	N/A	N/A	Not Optionable
NSPX Inspyr Therapeutics	1	543.15 million	N/A	Not Optionable

ETST, NSPX, IMUC, and CDXI Headlines

Source	Headline
	EWTX Edgewise Therapeutics, Inc. seekingalpha.com - April 4 at 4:26 PM
	FAST joins with University of Pennsylvania to develop investigational AAV gene therapy for Angelman syndrome news-medical.net - October 18 at 1:51 PM
	Memo Therapeutics gets US FDA fast track designation for AntiBKV as treatment of BKV infection in renal transplant patients pharmabiz.com - May 5 at 9:05 PM
	Decibel Therapeutics gets European orphan drug designation for lead gene therapy candidate DB-OTO pharmabiz.com - April 3 at 3:42 PM
	BrainStorm Cell Therapeutics announces US FDA committee to review BLA for NurOwn to treat amyotrophic lateral sclerosis pharmabiz.com - March 29 at 3:34 PM
	Kuria Therapeutics completes US FDA pre-IND consultation for topical Nrf2 activator for corneal endothelial disease pharmabiz.com - March 22 at 2:20 PM
	Combined Therapeutics’ mRNA vaccine platform receives US patent pharmabiz.com - March 16 at 2:13 AM
	TG Therapeutics Stock (NASDAQ:TGTX), Analyst Ratings, Price Targets, Predictions benzinga.com - March 4 at 3:07 AM
	Inspyr Therapeutics Announces New Holding Company Structure and Reverse Stock Split ca.finance.yahoo.com - October 12 at 7:31 AM

Media Sentiment Over Time

Company Descriptions

Cardax

OTCMKTS:CDXI

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiovascular inflammation and dyslipidemia, with a target indication of severe hypertriglyceridemia; and CDX-301, a zeaxanthin pharmaceutical candidate for macular degeneration. Cardax, Inc. is based in Honolulu, Hawaii.

Earth Science Tech

OTCMKTS:ETST

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

EOM Pharmaceuticals

OTCMKTS:IMUC

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Inspyr Therapeutics

OTCMKTS:NSPX

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial